Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q1 2025 Earnings Presentation
19 slides from Acadia Pharmaceuticals's earnings presentation, May 7, 2025
Slide 1: First Quarter 2025 Earnings Call
First Quarter 2025 Earnings Call MAY 7, 2025
Slide 2: Call Agenda
Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Catherine Owen Adams | Chief Executive Officer Commercial Update Tom Garner | Executive Vice President, Chief Commercial Officer R&D Update Elizabeth H.Z. Thompson | Executive
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams CHIEF EXECUTIVE OFFICER 4
Slide 5: First Quarter Highlights
First Quarter Highlights Q1 Total Revenues of $244.3 million, up 19% year-over year Q1 2025 sales of $84.6 million, Q1 2025 sales of $159.7 million, up 11% year-over-year up 23% year-over-year Highest ever number of patients receiving Continued momentum from consumer shipments during the quarter act
Slide 6: Commercial Update
Commercial Update Tom Garner CHIEF COMMERCIAL OFFICER 6
Slide 7: DAYBUE First Quarter Update
DAYBUE First Quarter Update KEY DRIVERS ▷ 954 unique patients received DAYBUE $84.6M in Q1 Net Product Sales ▷ Discontinuations down 35% compared to Q4 2024 Up 11% vs. Q1 2024 and 66% compared to Q1 2024 ▷ 65% of active patients have now been on therapy 12 months or longer ▷ Continued steady persist
Slide 8: Update on DAYBUE Global Expansion Plans
Update on DAYBUE Global Expansion Plans EU | Est 9,000 – 12,000 prevalent patients ▷ Preparing for anticipated approval in Q1 2026 ▷ First Rett syndrome patient served in Germany under managed access program ▷ Strengthened EU launch preparation by hiring experienced leadership team REST OF THE WORLD
Slide 9: NUPLAZID First Quarter Updates
NUPLAZID First Quarter Updates KEY DRIVERS $159.7M ▷ Increasing awareness of Parkinson's related in Q1 Net Product Sales hallucinations and delusions through unbranded Up 23% year-over-year; diseases awareness campaign highest ever quarterly sales ▷ Continued leverage of published Real World Evidenc
Slide 10: R&D Update
R&D Update Elizabeth H.Z. Thompson E X E C U T I V E V I C E P R E S I D E NT | H E A D O F R E S E A R C H A ND D E V E L O P M E NT 10
Slide 11: Accelerated Timeline for ACP-101 in Prader Willi Syndrome
Accelerated Timeline for ACP-101 in Prader Willi Syndrome ▷ Last patient-in now expected in Q2 2025 due to strong interest from PWS community and diligence of Acadia team ▷ Topline results expected to follow in early Q4 2025 ▷ Assuming positive data, anticipate filing NDA in Q1 2026 Prader-Willi Syn
Slide 12: ACP-204 Clinical Programs
ACP-204 Clinical Programs ACP-204 is a new 5HT2A inverse agonist designed based on learnings from Pimavanserin Alzheimer's Disease Psychosis (ADP) Lewy Body Dementia Psychosis (LBDP) ▷ Neurodegenerative condition associated with abnormal deposits of alpha-synuclein in the ▷ Global, placebo-controlle
Slide 13: Deep and Diverse Pipeline Across CNS and Rare Disease
Deep and Diverse Pipeline Across CNS and Rare Disease PROGRAM INDICATION MECHANISM OF ACTION DISCOVERY IND ENABLING PHASE 1 PHASE 2 PHASE 3 LAUNCHED CNS NUPLAZID Parkinson's Disease Psychosis 5HT2A inverse agonist ACP-204 Alzheimer's Disease Psychosis New 5HT2A inverse agonist ACP-204 Lewy Body Deme
Slide 14: Financial Update
Financial Update Mark Schneyer CHIEF FINANCIAL OFFICER 14
Slide 15: Q1 2025 Financial Highlights
Q1 2025 Financial Highlights Millions, Except EPS 1Q25 1Q24 YoY Change TOTAL Revenue $244.3 $205.8 19% NUPLAZID $159.7 $129.9 23% DAYBUE $84.6 $75.9 11% R&D $78.3 $59.7 31% SG&A $126.4 $108.0 17% Net Income $19.0 $16.6 14% EPS $0.11 $0.10 10% Cash Balance $681.6 15
Slide 16: FY 2025 Financial Guidance
FY 2025 Financial Guidance Guidance NUPLAZID Net Sales $650 to $690 Million NUPLAZID Gross-to-Net 22.5% to 25.5% DAYBUE Net Sales $380 to $405 Million DAYBUE Gross-to-Net 21.5% to 24.5% Total Revenue $1.03 to $1.095 Billion $330 to $350 Million R&D Expense (Updated from prior guidance of $310 to $33
Slide 17: Concluding Remarks
Concluding Remarks Catherine Owen Adams = CHIEF EXECUTIVE OFFICER 17
Slide 18: 2025-2026 Anticipated Milestones
2025-2026 Anticipated Milestones 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Anticipated Filed MAA Managed access programs Approval in with EMA available in certain countries EMA ACP-101 Phase 3 Phase 3 NDA Potential LAST PATIENT IN TOPLINE RESULTS Filing Approval (PWS) Phase 2 Phase 2 Phase 2 ACP-204 in LBDP
Slide 19: Q&A Session
Q&A Session 19
ACADIA Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix